CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKT-induced upregulation of MMP2/MMP9

International Journal of Oncology

Volumn 47, Issue 2, 2015, Pages 690-700

  Gao, Ye ^a   Guan, Zhenfeng ^a   Chen, Jiaqi ^a   Xie, Hongjun ^a   Yang, Zhao ^a   Fan, Jinhai ^a   Wang, Xinyang ^a   Li, Lei ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Bladder cancer; CXCL5; CXCR2; Invasion; Migration; MMP2; MMP9; PI3K AKT

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GELATINASE A; GELATINASE B; PHOSPHATIDYLINOSITOL 3 KINASE; CXCL5 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER METASTASIS; CANCER CELL; CANCER GRADING; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; UPREGULATION; BLADDER TUMOR; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CHEMOKINE CXCL5; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, INTERLEUKIN-8B; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84932607211     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3041     Document Type: Article

References (30)

1. Yan Y, Liang H, Li T, Li M, Li R, Qin X and Li S: The MMP-1, MMP-2, and MMP-9 gene polymorphisms and susceptibility to bladder cancer: A meta-analysis. Tumour Biol 35: 3047-3052, 2014.
2. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507: 315-322, 2014.
3. Kanayama H: Matrix metalloproteinases and bladder cancer. J Med Invest 48: 31-43, 2001.
4. Vargová V, Pytliak M and Mechírová V: Matrix metalloproteinases. EXS 103: 1-33, 2012.
5. Lai WC, Zhou M, Shankavaram U, Peng G and Wahl LM: Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J Immunol 170: 6244-6249, 2003.
6. Westermarck J and Kähäri VM: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13: 781-792, 1999.
7. Chung TW, Lee YC and Kim CH: Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: Involvement of invasive potential. FASEB J 18: 1123-1125, 2004.
8. Cheng JC, Chou CH, Kuo ML and Hsieh CY: Radiationenhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 25: 7009-7018, 2006.
9. Adya R, Tan BK, Punn A, Chen J and Randeva HS: Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: Novel insights into visfatin-induced angiogenesis. Cardiovasc Res 78: 356-365, 2008.
10. Sen M, Reifert J, Lauterbach K, Wolf V, Rubin JS, Corr M and Carson DA: Regulation of fibronectin and metalloproteinase expression by Wnt signaling in rheumatoid arthritis synoviocytes. Arthritis Rheum 46: 2867-2877, 2002.
11. Yang JM, Xu Z, Wu H, Zhu H, Wu X and Hait WN: Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 1: 420-427, 2003.
12. S ethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, et al: Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5: 662-668, 1999.
13. Lee HJ, Song IC, Yun HJ, Jo DY and Kim S: CXC chemokines and chemokine receptors in gastric cancer: From basic findings towards therapeutic targeting. World J Gastroenterol 20: 1681-1693, 2014.
14. Mukaida N and Baba T: Chemokines in tumor development and progression. Exp Cell Res 318: 95-102, 2012.
15. Gorbachev AV and Fairchild RL: Regulation of chemokine expression in the tumor microenvironment. Crit Rev Immunol 34: 103-120, 2014.
16. Kawamura M, Toiyama Y, Tanaka K, Saigusa S, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y and Kusunoki M: CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur J Cancer 48: 2244-2251, 2012.
17. Zhou SL, Dai Z, Zhou ZJ, Chen Q, Wang Z, Xiao YS, Hu ZQ, Huang XY, Yang GH, Shi YH, et al: CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils. Carcinogenesis 35: 597-605, 2014.
18. Kuo PL, Chen YH, Chen TC, Shen KH and Hsu YL: CXCL5/ ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway. J Cell Physiol 226: 1224-1231, 2011.
19. Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM and Macoska JA: CXCL5 promotes prostate cancer progression. Neoplasia 10: 244-254, 2008.
20. Park JY, Park KH, Bang S, Kim MH, Lee JE, Gang J, Koh SS and Song SY: CXCL5 overexpression is associated with late stage gastric cancer. J Cancer Res Clin Oncol 133: 835-840, 2007.
21. Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS and Yeudall WA: Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res 66: 4279-4284, 2006.
22. Zheng J, Zhu X and Zhang J: CXCL5 knockdown expression inhibits human bladder cancer T24 cells proliferation and migration. Biochem Biophys Res Commun 446: 18-24, 2014.
23. Toker A and Marmiroli S: Signaling specificity in the Akt pathway in biology and disease. Adv Biol Regul 55: 28-38, 2014.
24. Yang Z, Li Z, Feng H, Bian X, Liu Y and Liu Y: Enhanced growth inhibition by combined two pathway inhibitors on K-ras mutated non-small cell lung cancer cells. Zhonghua Zhong Liu Za Zhi 36: 645-650, 2014 (In Chinese).
25. Polivka J Jr and Janku F: Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 142: 164-175, 2014.
26. Houédé N and Pourquier P: Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: Its potential use in the treatment of bladder cancers. Pharmacol Ther 145: 1-18, 2015.
27. Martini M, De Santis MC, Braccini L, Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An updated review. Ann Med 46: 372-383, 2014.
28. Heavey S, O'Byrne KJ and Gately K: Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat Rev 40: 445-456, 2014.
29. Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, et al: CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73: 571-582, 2013.
30. Würth R, Bajetto A, Harrison JK, Barbieri F and Florio T: CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci 8: 144, 2014.